Synlogic, Inc. announced the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria (PKU). As a result, Synlogic?s management and its Board of Directors have made the decision to evaluate strategic options for the Company. As a result of this process, Synlogic will cease operations, and reduce its workforce by more than 90%, retaining only certain employees to assist in the strategic review and assist in the discontinuation of the study.

The majority of impacted roles will end in February 2024.